Get the Stockscreener App
322.17
0.32%
1.03
After Hours:
322.17
Penumbra Inc stock is traded at $322.17, with a volume of 174.06K.
It is up +0.32% in the last 24 hours and down -0.63% over the past month.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
See More
Previous Close:
$321.14
Open:
$321
24h Volume:
174.06K
Relative Volume:
0.50
Market Cap:
$12.69B
Revenue:
$1.45B
Net Income/Loss:
$171.05M
P/E Ratio:
74.13
EPS:
4.3459
Net Cash Flow:
$212.73M
1W Performance:
+0.15%
1M Performance:
-0.63%
6M Performance:
-5.14%
1Y Performance:
+15.18%
1-Day Range:
$321.00
$322.72
1-Week Range:
$320.97
$325.00
52-Week Range:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
322.17 | 12.75B | 1.45B | 171.05M | 212.73M | 4.3459 |
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-25 | Initiated | Wells Fargo | Underweight |
| Oct-08-25 | Upgrade | Needham | Hold → Buy |
| Sep-02-25 | Initiated | Evercore ISI | Outperform |
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Penumbra, Inc. (PEN): Growth Potential Amidst Analyst Consensus And Market Dynamics - DirectorsTalk Interviews
Discipline and Rules-Based Execution in PEN Response - Stock Traders Daily
BSP:P2NB34 Shareholder Yield %: 0.05% | Fairly Valued - GuruFocus
BSP:P2NB34 Revenue: R$7,963 Mil | Fairly Valued - GuruFocus
Penumbra Stock Price Forecast. Should You Buy PEN? - StockInvest.us
BSP:P2NB34 GF Value: R$57.41 | Fairly Valued - GuruFocus
BSP:P2NB34 ROCE %: 10.74% | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Loans Receivable : R$0 Mil (As of Jun. 2026) - GuruFocus
BSP:P2NB34 3-Year EPS without NRI Growth Rate: 188.40% — 5 - GuruFocus
Penumbra (BSP:P2NB34) Land And Improvements : R$0 Mil (As of Jun. 2026) - GuruFocus
Q3 2025 Penumbra Inc Earnings Call Transcript - GuruFocus
BSP:P2NB34 Other Current Assets: R$268 Mil | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Total Long-Term Assets : R$3,231 Mil (As of Jun. 2026) - GuruFocus
BSP:P2NB34 Net Income: R$853 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 FCF Yield %: 1.79 — 2457% Above Median - GuruFocus
BSP:P2NB34 Market Cap: R$2,172 Mil | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) 12-1 Month Momentum % : N/A% (As of Sep. 05, 2026) - GuruFocus
BSP:P2NB34 3-Year RORE %: 46.88 | Fairly Valued - GuruFocus
BSP:P2NB34 PE Ratio (TTM): 2.55 — 99% Below Median - GuruFocus
Penumbra (BSP:P2NB34) Other Income (Minority Interest) : R$0 Mil (TTM As of Jun. 2026) - GuruFocus
Penumbra (BSP:P2NB34) Repurchase of Stock : R$0 Mil (TTM As of Jun. 2026) - GuruFocus
BSP:P2NB34 Forward PE Ratio: 1.72 | Fairly Valued - GuruFocus
Penumbra Inc Stock Operating Data - GuruFocus
BSP:P2NB34 Pre-Tax Income: R$1,082 Mil | Fairly Valued - GuruFocus
Penumbra, Inc. (PEN) Stock Analysis: Unraveling The 12.48% Potential Upside - DirectorsTalk Interviews
Incuvate Files Patent Infringement Lawsuit Against Penumbra - The Manila Times
Trillium Asset Management LLC Acquires New Stake in Penumbra, Inc. $PEN - MarketBeat
BlackRock Inc. Invests $1.36 Billion in Penumbra, Inc. $PEN - MarketBeat
Incuvate Says Penumbra Infringed Blood Clot Detection System (1) - Bloomberg Law News
Penumbra, Inc. (NYSE:PEN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Penumbra (NYSE: PEN) grants president 3,060 RSUs with multi-year vesting - Stock Titan
Penumbra (PEN) Results at a Glance: Reported EPS Misses Expectations for This Review; Trading-Day Reaction: The Share Price Sheds 0.74% in the Available RecordForward Guidance Trends - vinanet.vn
NINE MASTS CAPITAL Ltd Acquires New Position in Penumbra, Inc. $PEN - MarketBeat
Citizens Financial Group Inc. RI Invests $9.88 Million in Penumbra, Inc. $PEN - MarketBeat
Penumbra, Inc. (PEN) Stock Analysis: Exploring a 10.65% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Fidelity Advisor Mid Cap II Fund's Penumbra Inc(PEN) Holding History - GuruFocus
Alberta Investment Management Corp Invests $10.46 Million in Penumbra, Inc. $PEN - MarketBeat
Neurothrombectomy Devices Market Size, Share | Growth [2034] - Fortune Business Insights
S&CO Inc. Takes Position in Penumbra, Inc. $PEN - MarketBeat
Technical Reactions to PEN Trends in Macro Strategies - Stock Traders Daily
Penumbra, Inc.: Financial Data Forecasts Estimates and Expectations | PEN | US70975L1070 - marketscreener.com
Barclays PLC (PEN) discloses 2.34M-share beneficial stake in Penumbra Inc - Stock Titan
Should Penumbra’s RED 68 Catheter Recall and Margin Strain Require Action From Penumbra (PEN) Investors? - webull.com
Penumbra, Inc. (PEN) stock price, news, quote and history - Yahoo Finance Singapore
Penumbra, Inc. (PEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Washington Trust Advisors, Inc.'s Penumbra Inc(PEN) Holding History - GuruFocus
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care - Nonstop Local News Montana
Penumbra, Inc. (PEN) Stock Analysis: Evaluating the 11.45% Potential Upside in Medical Devices - DirectorsTalk Interviews
Penumbra Inc (PEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bank of America Corp DE Sells 46,436 Shares of Penumbra, Inc. $PEN - MarketBeat
Royal Bank of Canada Decreases Holdings in Penumbra, Inc. $PEN - MarketBeat
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):